Do you guys think that Sandoz would accept the entry of another generic just so Momenta could receive some type of reimbursement from Amphastar.
Of course not. But the back-off portion of the deals are more favorable to NVS than MNTA.
You want to look at a portion and not the totality, and in that you are wrong. If the totality of the deal is fair, then it does not matter if the royalties portion favors MNTA.
Market Data 
Markets 
AI
